Mustang Bio (MBIO) Q3 2025 earnings summary

Executive summary

• Focused on developing CAR T therapies for hematologic malignancies, autoimmune diseases, and solid tumors, with key partnerships and ongoing clinical trials for MB-101, MB-108, and MB-106.

• No product sales to date; all programs remain in clinical or preclinical stages, with substantial operating losses expected to continue.

• Significant pipeline developments include FDA Orphan Drug Designations for MB-101 and MB-108, and a planned investigator-sponsored trial for MB-109 in 2026.

Financial highlights

• Net loss for the nine months ended September 30, 2025, was $1.4 million, a significant improvement from a $14.8 million loss in the same period in 2024.

• Cash and cash equivalents were $19.0 million as of September 30, 2025, up from $6.8 million at the start of the year.

• Operating expenses decreased sharply due to workforce reductions, lease terminations, and program closures.

• Net cash used in operating activities was $3.5 million for the nine months ended September 30, 2025, compared to $9.4 million in the prior year.

• Financing activities provided $14.5 million, including proceeds from a February 2025 equity offering and warrant exercises.

Outlook and guidance

• Substantial doubt exists about the ability to continue as a going concern for the next 12 months without additional capital.

• Plans to seek further funding through equity offerings, partnerships, or licensing arrangements.

• Ongoing cost containment measures, including facility closures and workforce reductions, to preserve capital.